AV-1980R 20 µg

Phase 1Biologic

IInstitute for Molecular Medicine

AV-1980R 20 µg is one of 43 biologic programs targeting Alzheimer disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseRecruiting

Alzheimer DiseasePhase 1

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Leqembi

Eisai

Approved

1 2

Dayvigo

Eisai

Approved

1 3

Avelox

Victoza

Avandia

Estrace

Aleve

Epidiolex

Cialis

Rifadin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Alzheimer Disease

NCT07158905

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

A Phase I, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of AV-1980R in Participants With Preclinical Alzheimer's Disease

Recruiting·IInstitute for Molecular Medicine·Phase 1·NCT07158905·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AV-1980R 20 µg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AV-1980R 20 µg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AV-1980R 20 µg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute for Molecular Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IInstitute for Molecular Medicine

AV-1980R 20 µg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News